A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer

Part of paid clinical trials in Basking Ridge, New Jersey.

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT07631000
Phase
PHASE2
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cadonilimab — DRUG
    Perioperative cadonilimab plus neoadjuvant chemotherapy

Study Details

The purpose of this study is to find out whether adding cadonilimab to the usual chemotherapy approach is an effective and safe treatment for participants with locally advanced/resectable gastric cancer or gastroesophageal junction (GEJ) cancer

Key Dates

Start date
May 27, 2026
Status verified
Jun 2026
Primary completion
May 27, 2029
Completion
May 27, 2029

Study Design

Enrollment
37 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Participants with HER2-negative gastric or GEJ adenocarcinoma
    Participants will have locally advanced, resectable, HER2-negative gastric or GEJ adenocarcinoma

Primary Outcome Measure

Event-free survival (EFS) rata [ Time Frame: 18 months ]

Central Contacts

Locations (7)

Find similar trials in Basking Ridge, NJ

By condition

Related Studies